Published in Cancer Biother Radiopharm on June 01, 1997
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2009) 1.38
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol (2010) 1.37
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol (2006) 1.24
Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res (2009) 0.93
Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br J Cancer (2007) 0.89
Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells. Proc Natl Acad Sci U S A (1999) 0.87
Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Semin Oncol (2014) 0.85
Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother (2008) 0.84
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer (2005) 0.82
Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. Clin Dev Immunol (2011) 0.81
The spectrum of use of rituximab in chronic lymphocytic leukemia. Onco Targets Ther (2010) 0.80
One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med (2011) 0.79
Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. BMC Cancer (2005) 0.79
Therapeutic monoclonal antibodies in oncology. J R Soc Med (2005) 0.79
Expanded use of rituximab in the management of non-Hodgkin lymphoma. Onco Targets Ther (2009) 0.78
Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Ther Adv Musculoskelet Dis (2014) 0.78
Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis. For Immunopathol Dis Therap (2013) 0.78
Clinical use of biologics in vasculitis syndromes. Biologics (2012) 0.76
A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR. J Cancer Res Clin Oncol (2015) 0.75
The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies. Ther Adv Hematol (2016) 0.75
Transient wheal attack corresponding to the tumor lesions of primary cutaneous diffuse large B cell lymphoma, leg type after successive rituximab treatment. Case Rep Dermatol (2014) 0.75
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Novel hippocampal interneuronal subtypes identified using transgenic mice that express green fluorescent protein in GABAergic interneurons. J Neurosci (2000) 4.36
Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene (2006) 4.06
TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest (1994) 2.43
Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med (2001) 2.35
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol (2006) 2.13
Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J (2006) 2.11
A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst (1984) 2.08
Gore-Tex patch repair of the anterior rectus sheath in free rectus abdominis muscle and myocutaneous flaps. Plast Reconstr Surg (1996) 2.04
Is hand, foot and mouth disease associated with meteorological parameters? Epidemiol Infect (2010) 1.99
Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. J Immunol (1979) 1.80
Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy (2011) 1.73
Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: multicentre randomised controlled trial and economic evaluation of antimicrobial- and antiseptic-impregnated urethral catheters (the CATHETER trial). Health Technol Assess (2012) 1.66
Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes. J Exp Med (1989) 1.60
Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res (2001) 1.59
Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J Immunol (1981) 1.58
Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol (1988) 1.54
Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.53
Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst (1980) 1.49
Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J Natl Cancer Inst (1995) 1.47
Human tear lysozyme. II. Quantitative determination with standard Schirmer strips. Am J Ophthalmol (1968) 1.46
Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans (1997) 1.45
Evidence for several cell populations active in antibody dependent cellular cytotoxicity. J Immunol (1973) 1.44
Parent comprehension of polio vaccine information pamphlets. Pediatrics (1996) 1.44
An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis (1988) 1.43
The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem (1991) 1.42
Analysis of VSV mutant with attenuated cytopathogenicity: mutation in viral function, P, for inhibition of protein synthesis. Cell (1977) 1.41
Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine. Anesth Analg (1990) 1.40
Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. J Immunol (1992) 1.39
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene (2009) 1.34
Cellular immunoadsorbents: a simplified technique for separation of lymphoid cell populations. J Immunol (1974) 1.34
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33
Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys (2000) 1.32
Expression of metastatic potential of tumor cells in young nude mice is correlated with low levels of natural killer cell-mediated cytotoxicity. Int J Cancer (1980) 1.31
The SJL/J T cell response to both spontaneous and transplantable syngeneic reticulum cell sarcoma is mediated predominantly by the V beta 17a+ T cell clonotype. J Exp Med (1988) 1.30
Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol (1996) 1.30
Mechanism of cell-mediated cytotoxicity at the single cell level. II. Evidence for first-order kinetics of T cell-mediated cytolysis and for heterogeneity of lytic rate. J Immunol (1979) 1.29
SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet (2009) 1.28
Selective lysis of NK-sensitive target cells by a soluble mediator released from murine spleen cells and human peripheral blood lymphocytes. J Immunol (1981) 1.26
Evidence for a susceptibility gene, SLEV1, on chromosome 17p13 in families with vitiligo-related systemic lupus erythematosus. Am J Hum Genet (2001) 1.26
Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J Immunol (1984) 1.25
Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J Biol Chem (1989) 1.25
Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol (1999) 1.24
Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol (2000) 1.23
Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer (2002) 1.22
Mode of action of interferon-mediated modulation of natural killer cytotoxic activity: recruitment of pre-NK cells and enhanced kinetics of lysis. J Immunol (1980) 1.21
Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry (1986) 1.19
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res (1995) 1.15
Role of natural killer cells in control of cancer metastasis. Cancer Metastasis Rev (1982) 1.15
Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene (1989) 1.15
A 55-kilodalton antigen encoded by a gene on a Borrelia burgdorferi 49-kilobase plasmid is recognized by antibodies in sera from patients with Lyme disease. Infect Immun (1995) 1.14
Histamine-receptor leucocytes (HRL). Organ and lymphoid subpopulation distribution in man. Clin Exp Immunol (1977) 1.13
Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Anticancer Agents (2003) 1.13
Concanavalin A-mediated activation of antigen-primed lymphocytes into secondary cytotoxic lymphocytes. J Exp Med (1977) 1.13
Histamine receptor-bearing leukocytes (HRL). I. Detection of histamine receptor-bearing cells by rosette formation with histamine-coated erythrocytes. J Immunol (1974) 1.13
Antibody-dependent cellular cytotoxicity against HIV-coated target cells by peripheral blood monocytes from HIV seropositive asymptomatic patients. J Immunol (1990) 1.13
Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol (1997) 1.11
Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cell Immunol (1995) 1.11
Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis (2008) 1.10
Randomised controlled trial of a guided self-help treatment on the Internet for binge eating disorder. Behav Res Ther (2011) 1.09
Mechanisms of depressed reactivity to dinitrochlorobenzene and ultraviolet-induced tumors during ultraviolet carcinogenesis in BALB/c mice. Cell Immunol (1978) 1.09
Role of natural killer cells in host defense against cancer metastasis. Symp Fundam Cancer Res (1983) 1.08
Antibody-dependent cellular cytotoxicity (ADCC)-mediated destruction of human immunodeficiency virus (HIV)-coated CD4+ T lymphocytes by acquired immunodeficiency syndrome (AIDS) effector cells. J Clin Immunol (1988) 1.07
Abnormal balance in the angiopoietin-tie2 system in human brain arteriovenous malformations. Circ Res (2001) 1.06
Expression of metastatic potential of allogenic and xenogeneic neoplasms in young nude mice. Cancer Res (1981) 1.06
Lectin-dependent cellular cytotoxicity in man. Transplantation (1977) 1.06
Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment. J Immunol (1983) 1.06
Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120. J Immunol (1993) 1.06
Sexual transmission of human papillomaviruses in heterosexual and male homosexual couples, studied by DNA hybridisation. Genitourin Med (1988) 1.05
"Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology (N Y) (1992) 1.04
Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J Clin Immunol (1995) 1.04
Identification and characterization of a human T cell line-derived lymphokine with MAF-like activity distinct from interferon-gamma. J Immunol (1986) 1.04
Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene (2007) 1.04
Effects of prostaglandins and cAMP levels on monocyte IL-1 production. Agents Actions (1989) 1.03
Antibody dependent cellular cytotoxicity: cytotoxicity mediated by non t-lymphocytes. Clin Immunol Immunopathol (1974) 1.03
Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma. Cancer Treat Res (2007) 1.03
Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol (1991) 1.03
Macrophage activation in rat models of inflammation and arthritis. Systemic activation precedes arthritis induction and progression. Arthritis Rheum (1986) 1.02
Specific antibodies to dinucleotides and trinucleotides. Eur J Biochem (1972) 1.02
The role of natural killer cells in the control of tumor growth and metastasis. Biochim Biophys Acta (1985) 1.02
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol (2007) 1.02
Requirement for human red blood cells in inactivation of C3b in immune complexes and enhancement of binding to spleen cells. J Immunol (1983) 1.02
Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene (2006) 1.02
Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun (1999) 1.02
The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol Immunother (1997) 1.01
In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother (1997) 1.01
CD3-associated heterodimeric polypeptides on suppressor hybridomas define biologically active inhibitory cells. Proc Natl Acad Sci U S A (1988) 1.00
SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem Pharmacol (1987) 0.99
Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. Dis Esophagus (2006) 0.99
Cloning of a functional gene responsible for the expression of a cell surface antigen correlated with human chronic lymphocytic leukemia. Cell (1981) 0.99